Serum beta 2-microglobulin in malignant lymphoproliferative disorders.

Area of Science:

• Hematology
• Oncology
• Biochemistry

Background:

• Beta 2-microglobulin (B2m) is a protein found on the surface of most nucleated cells.
• Its serum levels can be elevated in various conditions, including lymphoproliferative disorders.

Purpose of the Study:

• To evaluate the diagnostic and prognostic utility of serum B2m levels in a cohort of patients with diverse lymphoproliferative disorders.
• To correlate B2m levels with disease characteristics, treatment response, and clinical outcomes.

Main Methods:

• Serum B2m levels were measured in 274 patients diagnosed with acute and chronic lymphoproliferative disorders.
• Patients included those with non-Hodgkin lymphomas (NHL), Hodgkin lymphomas (HL), B-cell chronic lymphocytic leukemia (B-CLL), Waldenström macroglobulinemia (WM), multiple myeloma (MM), acute lymphoblastic leukemia (ALL), and hairy cell leukemia (HCL).
• B2m levels were analyzed at diagnosis and during/after therapy, correlating with clinical stage, histology, immunoglobulin type, immunophenotype, and treatment response.

Main Results:

• Elevated pretreatment B2m levels were observed in advanced stages of NHL and HL, B symptoms, and unfavorable NHL subtypes.
• A strong correlation between B2m levels and tumor cell mass was found in B-CLL and MM.
• Serum B2m levels decreased significantly with treatment and increases could predict relapse in B-CLL and MM.
• In ALL, serum B2m levels were only slightly elevated above normal ranges.

Conclusions:

• Serum B2m is a valuable indicator of tumor burden, particularly in multiple myeloma and B-cell chronic lymphocytic leukemia.
• While B2m reflects disease extent in lymphomas, its prognostic significance is less pronounced compared to MM and B-CLL.
• Monitoring B2m levels can aid in assessing treatment response and detecting relapse in specific lymphoproliferative malignancies.